Aptatek Biosciences Advances PheCheck™ Clinical Validation with Patient Enrollment Underway
Aptatek Biosciences, Inc., a clinical-stage diagnostics company developing connected, aptamer-enabled technologies for decentralized metabolic monitoring, today announced that patient enrollment is underway in the PheCheck™ Validation Study (NCT07551921), advancing the company’s lead investigational program into formal clinical validation.
Full article text belongs to the original publisher. Moogle News shows the headline/summary and sends you to the source.
Read full story on publisher site →